CD14 and invasive ductal breast carcinoma: Furthermore, MBC patients tend to have higher levels of systemic CD16+ monocyte subpopulations compared to healthy donors [22], and a previous study has indicated that CD14+CD16+ monocytes (comprising both intermediate and non-classical monocytes) associate inversely with tumor size in patients with invasive ductal carcinoma, especially at early stages [32].